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Aims: The aim was to review epidemiologic studies to reassess whether serum levels of 
triglycerides should be considered independently of high-density lipoprotein-cholesterol 
(HDL-C) as a predictor of coronary heart disease (CHD).
Methods and results: We systematically reviewed population-based cohort studies in which 
baseline serum levels of triglycerides and HDL-C were included as explanatory variables in 
multivariate analyses with the development of CHD (coronary events or coronary death) as 
dependent variable. A total of 32 unique reports describing 38 cohorts were included. The 
independent association between elevated triglycerides and risk of CHD was statistically sig-
niﬁ  cant in 16 of 30 populations without pre-existing CHD. Among populations with diabetes 
mellitus or pre-existing CHD, or the elderly, triglycerides were not signiﬁ  cantly independently 
associated with CHD in any of 8 cohorts. Triglycerides and HDL-C were mutually exclusive 
predictors of coronary events in 12 of 20 analyses of patients without pre-existing CHD.
Conclusions: Epidemiologic studies provide evidence of an association between triglycerides 
and the development of primary CHD independently of HDL-C. Evidence of an inverse 
relationship between triglycerides and HDL-C suggests that both should be considered in CHD 
risk estimation and as targets for intervention.
Keywords: coronary heart disease, triglycerides, high-density lipoprotein-cholesterol, low-density 
lipoprotein-cholesterol, hypercholesterolemia
Introduction
Serum cholesterol levels are important components of guidelines for determining risk 
and treatment of coronary heart disease (CHD). Low-density lipoprotein-cholesterol 
(LDL-C), the primary component of total cholesterol, is recognized as the most 
important lipid risk factor. Cardiovascular risk assessment in US and UK guidelines 
is based on the Framingham algorithm, in which the 10-year risk of CHD is calculated 
from levels of total cholesterol and high-density lipoprotein-cholesterol (HDL-C), and 
from demographic and clinical factors.1,2 Serum triglyceride levels are not a factor 
in quantifying CHD risk in these guidelines. A different basis for cardiovascular risk 
assessment has been adopted by the joint European societies.3 European guidelines 
base their treatment recommendations on the ten-year risk of coronary death, which 
is calculated from the plasma level of total cholesterol and nonlipid risk factors.4,5 
Both the UK and European guidelines, however, recognize that elevated triglycerides 
increase the risk of CHD.5–7
Triglycerides do appear in international guidelines in considering therapy. 
Hypertriglyceridemia is recognized as a therapeutic target in UK guidelines. 
In European and US guidelines, combined elevated triglycerides and low HDL-C are 
to be considered when deciding on therapy.
The position of triglycerides in the guidelines is largely secondary to that of 
HDL-C. Given that the relationship between triglycerides and CHD is based on Vascular Health and Risk Management 2009:5 90
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epidemiological studies, the objective here was to review 
the literature describing those studies to reassess whether 
triglycerides should be considered independently of HDL-C 
as a predictor of CHD and target for treatment.
Methods
Articles describing population-based cohort studies were 
identiﬁ  ed in a February 2008 update of searches described 
in published meta-analyses.8–10 Articles were included in this 
literature review if they met the following criteria: cohort 
study of risk of cardiovascular disease; measurement of 
triglycerides at baseline; a multiple regression analysis of 
the independent association between triglycerides and risk 
of CHD, with HDL-C as an explanatory variable; article 
published in the peer-reviewed literature; and article in 
English. A total of 46 articles met these inclusion criteria.11–56 
To avoid double counting, we considered only one analysis 
of any cohort (except for subpopulations) – typically the most 
recent publication meeting the inclusion criteria. Multiple 
articles reporting the Copenhagen Male Study (CMS),28–30 
Caerphilly and Speedwell Collaborative Heart Disease 
Studies (CSCHDS),15,52 Framingham Heart Study (FHS; 
for men but not women),20,51 Prospective Cardiovascular 
Münster Study (PROCAM),12–14 Lipid Research Clinics 
Prevalence and Mortality Follow-Up Study (LRC-FS),11,19 
Nurses’ Health Study (NHS),43,44 and occupational groups 
examined in Rome (ROG)35,36 cohorts typically agreed on 
the study result (signiﬁ  cance of the association between 
triglycerides and CHD) or reached a consensus. Two reports 
of the Multiple Risk Factor Intervention Trial (MRFIT) study 
disagreed, however: the 25-year follow-up analysis reported 
a significant association, whereas a 6.1-year follow-up 
did not (the article reporting the 25-year follow-up was 
used for the MRFIT study).11,22 After excluding duplicate 
reports of the same cohort, a report in which the outcome 
was all-cause deaths,24 and a report in which the outcome 
was heart failure,26 32 reports with coronary events or 
coronary death as outcome remained and were included in 
the analysis.11,14,18,20–23,25,27,30–32,34,36–50,52,54–56 As some articles 
described more than one cohort,11 more than one subpopulation 
of a cohort (eg, men and women separately), and we included 
only one outcome measure per cohort (coronary events only, 
if coronary deaths were also reported), results for a total 
of 38 different populations were included in the analysis. 
These populations were categorized as patients without 
pre-existing CHD or as “high risk populations” – deﬁ  ned as 
patients with diabetes, pre-existing CHD, or the elderly – and 
into men or women or men/women within these categories. 
The cohorts included were: among populations without 
pre-existing CHD, 17 for men (Atherosclerosis Risk in 
Communities study [ARIC],45 Canadian Community Health 
Survey [CCHS],54 CMS,30 CSCHDS,52 CUORE,23 FHS,20 
Göttingen Risk, Incidence and Prevalence Study [GRIPS],18 
Health Professional’s Follow-Up Study [HPFUS],40 Lipid 
Research Clinics Coronary Primary Prevention Trial 
[LRC-CPPT],11 Metabolic, Lifestyle, and Nutrition Assess-
ment in Young Adults [MELANY],55 MRFIT,22 the second 
Northwick Park Heart Study [NPHSII],48 Physician’s Health 
Study [PHS],46 PROCAM,14 Quebec Cardiovascular Study 
[QCVS],39 Uppsala Longitudinal Study of Adult Men 
[ULSAM],21 Western Collaborative Group Study [WCGS]25), 
2 for men/women (4CJ,27 Asia Paciﬁ  c Cohort Studies Col-
laboration [APCSC]38), and 5 for women (ARIC,45 CCHS,54 
FHS,20 NHS,44 Women’s Health Study [WHS]56) with 
coronary events as outcome, and 3 for men (Apolipoprotein 
Mortality Risk Study [AMORIS],50 LRC-FS,11 ROG36) and 
3 for women (AMORIS,50 Enlarged Waist with Elevated 
Triglycerides study [EWET],49 LRC-FS11) with coronary 
deaths as outcome; among high risk populations with coro-
nary events as outcome, 1 with diabetes (Kuopio32), 5 with 
diabetes without pre-existing CHD (HPFUS,31 ARIC,42 
SHS,34 UKPDS,47 NHS43), 1 of the elderly without prior MI 
(CHS41) or stroke, and 1 post-MI (THROMBO37).
The primary outcome measure was a multivariate 
estimate of the statistical signiﬁ  cance of the independent 
association between triglycerides and CHD, with HDL-C 
and other lipids (LDL-C, triglycerides, etc.) as explanatory 
variables. A secondary outcome measure was a univariate 
analysis of the statistical signiﬁ  cance of the association 
between triglycerides and CHD, typically based on an 
ANOVA comparison of triglyceride concentrations in 
patients who did and did not subsequently experience CHD. 
CHD was classiﬁ  ed as coronary events and coronary deaths. 
Outcomes described by authors as myocardial infarction 
(MI), CHD, or ischemic heart disease, were reclassiﬁ  ed as 
coronary events.
Examination of the articles indicated that no consistent 
definition of the independent variable (triglyceride 
concentration) was applied and, in most reports of multivariate 
models of the association between triglycerides and CHD, 
a P value was the only information provided, frequently as 
P   0.05 or nonsigniﬁ  cant (NS) (P   0.05). Therefore, a 
descriptive approach was taken: we enumerated the number 
of cohorts in which triglycerides were or were not a signiﬁ  cant 
independent predictor of CHD. We also summarized results 
by various study characteristics – the study population, study Vascular Health and Risk Management 2009:5 91
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size (patient-years of follow-up), fasting status of patients at 
baseline lipid measurement, the type of multivariate model 
(proportional hazards models or unconditional multiple 
logistic regression), the deﬁ  nition of the independent variable 
(triglyceride concentration), and lipid variables included in 
the model. We took the median point for these variables and 
simply enumerated the number of cohorts above and below the 
median in which triglycerides were independently associated 
with the development of CHD. The number of patient-years 
of follow-up was as reported in the original articles or, if not 
cited, was calculated from the number of patients and the 
average years of follow-up; if the average years of follow-up 
was not reported, the study duration was used.
Results
Consistent association between 
triglycerides and CHD in univariate 
analyses
In univariate analyses of patients without pre-existing CHD, 
the plasma triglyceride concentration was significantly 
associated with CHD in 16 of 16 cohorts with coronary 
events as outcome11,18,21,22,25,27,30,39,40,44–46,48,52,56 and in 6 of 
6 cohorts with coronary death as outcome.11,36,49,50 This was 
also the case in 5 of 5 studies of diabetic patients with coronary 
events as outcome.31,32,34,42,43 In only one study, in which 
patients had a prior MI, were triglycerides not signiﬁ  cantly 
associated with recurrent coronary events.37 Representative 
relative risks (RRs) of coronary events, adjusted for matching 
demographic and other nonlipid factors, were RR 2.41 (95% 
CI 1.43–4.07) for men in the HPFUS cohort and 3.5 (1.8–7.3) 
for women in the NHS cohort (RR comparing the top and 
bottom quintiles of triglyceride levels).40,44
Inconsistent association between 
triglycerides and CHD in multivariate 
models including HDL-C
The pertinent results of multivariate analyses in which 
triglycerides, HDL-C, and other lipids were entered as 
independent variables are summarized in Table 1. The 
relationship between triglycerides and subsequent coronary 
events or coronary death was statistically signiﬁ  cant in 
16 instances14,20,22,27,30,38,45,46,48–50,52,54–56 (CCHS,54 CMS,30 
CSCHDS,52 MELANY,55 MRFIT,22 NPHSII,48 PHS,46 and 
PROCAM14 for men; 4CJ27 and APCSC38 for men/women; 
and ARIC,45 AMORIS,50 CCHS,54 FHS,20 EWET,49 and 
WHS56 for women) and not signiﬁ  cant in 14 instances11,1
8,20,21,23,25,36,39,40,44,45,50 (ARIC,45 CUORE,23 FHS,20 GRIPS,18 
HPFUS,40 LRC-CPPT,11 QCVS,39 ULSAM,21 WCGS,25 
Table 1 Numbers of cohorts in which triglycerides were or were not predictive of CHD independently of HDL-C, by selected study 
characteristics
Characteristic Outcome variable Number of cohorts
Triglycerides 
signiﬁ  cant
Triglycerides not 
signiﬁ  cant
Total
All studies CHD 16 22 38
High-risk populations Coronary events 0 8 8
Primary populations
 All CHD 16 14 30
 Sex
  Women CHD 6 2 8
  Women/men CHD 2 0 2
  Men CHD 8 12 20
 Outcome  variable
  Coronary  death Coronary  deaths 2 4 6
  Coronary  events Coronary  events 14 10 24
 Cohort  size
    52,000 patient-years Coronary events 6 6 12
    52,000 patient-years Coronary events 8 4 12
 Triglyceride  measurement
  Fasting Coronary  events 9 10 19
  Nonfasting Coronary  events 6 0 6
Abbreviations: CHD, coronary heart disease (deﬁ  ned as either coronary events or coronary death).Vascular Health and Risk Management 2009:5 92
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AMORIS,50 LRC-FS,11 and ROG36 for men; and NHS44 and 
LRC-FS11 for women) in analyses of populations without 
pre-existing CHD. In studies of high risk populations, 
the relationship between triglycerides and subsequent 
coronary events was not statistically signiﬁ  cant in any of 
the 8 cohorts.31,32,34,37,41–43,47
Although inconclusive, there is some indication that 
the association between triglycerides and CHD may be 
more frequently detectable among women and among 
populations without pre-existing CHD. Among populations 
without pre-existing CHD, triglycerides were signiﬁ  cantly 
associated with CHD in 6 of 8 analyses of women,20,45,49,50,54,56 
2 of 2 analyses of men/women,27,38 and 8 of 20 analyses of 
men.14,22,30,46,48,52,54,55 As indicated, the relationship between 
triglycerides and coronary events was signiﬁ  cant in none of 
8 high risk populations.
The association between triglyceride levels and 
subsequent coronary events was not correlated with cohort 
size in populations without pre-existing CHD. In 12 cohorts 
of between 6,835 and 50,848 patient-years, the association 
was signiﬁ  cant in 6 cohorts; in 12 cohorts of 53,890 to 
796,671 patient-years, the association between triglyceride 
levels and subsequent coronary events was significant 
in 8 (cohorts not listed).
In an analysis of the WHS, Bansal and colleagues 
recently argued that nonfasting but not fasting triglyceride 
levels were independently associated with cardiovascular 
events (fasting triglycerides were signiﬁ  cantly predictive 
of coronary events when the proportional hazards model 
included as covariates age, blood pressure, smoking status, 
use of hormone replacement therapy, triglycerides, and 
HDL-C, but not when diabetes mellitus, body mass index, 
and high-sensitivity C-reactive protein were also added).56 
Referring to participants without pre-existing CHD, we 
observed that triglycerides were a signiﬁ  cant independent 
predictor of coronary events in 6 of 6 populations with 
nonfasting blood samples27,46,48,54,56 and 9 of 19 instances 
with fasting blood samples14,20,22,30,38,45,49,52,55 (Patients in all 
analyses of high risk populations provided fasting blood 
samples).
Details of the multivariate modeling did not appear to 
affect whether triglycerides were signiﬁ  cant. Both signiﬁ  cant 
and nonsigniﬁ  cant associations between triglycerides and 
coronary events occurred in both proportional hazards 
models (9 signiﬁ  cant14,22,27,38,48,54–56 and 3 nonsigniﬁ  cant11,21,23) 
and multiple logistic regression models (3 signiﬁ  cant30,46,52 
and 5 nonsigniﬁ  cant18,25,39,40,44). The independent variable 
(triglyceride concentration) was entered into some models as 
a continuous variable, sometimes log-transformed; in other 
cases, triglyceride concentration was treated as a categorical 
variable, and divided into tertiles, quartiles, or quintiles. 
However, the deﬁ  nition of the triglyceride variable did 
not appear to affect whether triglycerides were signiﬁ  cant 
(cohorts not listed). We also considered the lipid and nonlipid 
variables that were included in the models, but none of these 
factors appeared to vary systematically by triglyceride result. 
LDL-C, for example, was a signiﬁ  cant independent variable 
in 10 studies with coronary events as dependent variable, 
among which triglycerides were signiﬁ  cant in 414,22,30,48 and 
nonsigniﬁ  cant in 6.11,18,39,40,44,57 In 6 other studies, in which 
total cholesterol was signiﬁ  cant, triglycerides were signiﬁ  cant 
in 427,46,48,52 and nonsigniﬁ  cant in 2.23,25 And in 3 studies in 
which apolipoprotein B was signiﬁ  cant, triglycerides were 
signiﬁ  cant in 148 and nonsigniﬁ  cant in 2.40,57
Discussion
Statistically significant and quite strong negative 
correlations between triglycerides and HDL-C were 
reported in some of the cohorts analyzed, with values ranging 
from −0.26 to −0.58.32,38,40,44,46,51,52,56,58,59 Given this negative 
correlation, we considered whether triglycerides and HDL-C 
were mutually exclusive predictors of CHD. That is, we 
considered whether HDL-C and triglycerides were identiﬁ  ed 
in the same multivariate model as independent predictors 
of coronary events. Of 20 analyses with coronary events as 
outcome for patients without pre-existing CHD, there were 
6 instances in which HDL-C was a signiﬁ  cant independent 
predictor of CHD but triglycerides were not, and 6 instances 
in which triglycerides were signiﬁ  cant but HDL-C was not. 
There were 4 instances in which both triglycerides and 
HDL-C were signiﬁ  cant independent predictors of CHD and 
4 instances in which neither was signiﬁ  cant. This suggests 
that a negative correlation between triglycerides and HDL-C 
may have obscured the relationship between triglyceride 
levels and risk of CHD.
Previously, investigators have taken a meta-analytic 
approach to determine whether triglycerides are signiﬁ  cantly 
predictive of CHD independently of HDL-C.8–10,60 Beginning 
in 1996,8 these authors concluded that triglycerides were a risk 
factor for cardiovascular disease in the general population, 
independently of HDL-C. A pooled, multivariable-adjusted 
RR, with respect to a 1 mmol/L increase in serum triglycerides, 
was reported as RR 1.14 (95% CI 1.05–1.28) for six studies 
of men and RR 1.37 (95% CI 1.13–1.66) for two of studies 
of women.8 The most recent (2007) pooled analysis included 
11 articles reporting multivariable adjustment for HDLC.60 Vascular Health and Risk Management 2009:5 93
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The meta-analytic approach, however, is limited by a 
dependence on reporting in the literature of data in a form 
suitable for statistical pooling. Given the variety of analytic 
approaches taken in the primary studies, statistical pool-
ing across all studies depends on a process of assumption, 
inference, and imputation.61 In contrast, our descriptive 
approach did not require any particular data reporting format 
and allowed analysis of a much larger data set of 32 articles 
reporting 38 cohorts.
The epidemiological data in the current analysis provide 
support for triglycerides as a predictor of CHD indepen-
dently of HDL-C, but possibly only in certain categories 
of patient or level of CHD risk. Triglycerides were not 
independently predictive of CHD in 8 of 8 high risk cohorts, 
perhaps because the association between triglycerides and 
CHD is relatively weak and is outweighed by other factors 
in high-risk populations. Triglycerides were predictive of 
CHD independently of HDL-C in about half of the lower 
risk, primary cohorts. This may reﬂ  ect random error and a 
relatively weak association that might fall on either side of 
the cut-point of P = 0.05 (The disadvantage of our descriptive 
approach is that it does not account for the numerical strength 
of an association, but simply whether it falls on either side of 
a cut-point). Consistent with these arguments, triglycerides 
were most often (in 6 of 8 cohorts) independently predictive 
of CHD in the lower-risk, primary populations of women.
The data also point to the inverse correlation of 
triglycerides and HDL-C in their role as risk factors. The 
inverse relationship between triglyceride and HDL-C levels 
likely reﬂ  ects their respective participation in lipid transport 
and reverse cholesterol transport. The inverse relationship 
holds in the effects of lipid-modifying drugs. Niacin,62 
ﬁ  brates,62 statins,63,64 CETP inhibitors,65 and gemcabene66 
all concomitantly increase HDL-C and decrease triglyc-
eride levels. Certain genetic changes also have inverse 
effects on HDL-C and triglycerides. Mutations in ABCA1, 
a gene encoding a protein involved in cholesterol transport, 
result in lowered HDL-C and raised triglycerides levels, 
in conjunction with an increased risk of CHD.67 Similarly, 
a mutation in the gene encoding lipoprotein lipase, and 
causing a lipoprotein lipase deﬁ  ciency, decreases HDL-C 
levels, while increasing triglycerides levels and the risk 
of CHD.68–71 The opposite effects are seen with a muta-
tion in the lipoprotein lipase gene that results in increased 
enzyme activity: HDL-C is increased, while triglyceride 
levels and the risk of CHD are decreased.72,73 The inverse 
relationship does not seem to be absolute, however, since 
other genetic alterations indicate that the inverse relationship 
between HDL-C and triglyceride levels can be uncoupled. 
Subjects with an inherited hepatic lipase deﬁ  ciency have 
hypertriglyceridemia in combination with increased HDL-C, 
associated with premature atherosclerosis and increased risk 
of CHD.74–78 This suggests that the cardio-protective effect 
of elevated HDL-C is not seen in the absence of the inverse 
relationship with triglycerides.
Conclusions
Epidemiological evidence indicates that plasma triglyceride 
levels are predictive of CHD. The relationship between 
triglycerides and CHD is stronger and more consistently 
observed in populations without elevated CHD risk (eg, with-
out pre-existing CHD). Population based screening for 
elevated triglycerides may identify individuals at elevated 
risk for CHD who may not otherwise be detected. Multivariate 
analyses indicate that the strong inverse relationship between 
triglycerides and HDL-C may reﬂ  ect a common pathophysi-
ologic process. This suggests that high triglycerides or low 
HDL-C or both might be considered for use in CHD risk 
estimation and that both triglycerides and HDL-C may be 
considered targets for therapeutic or lifestyle interventions.
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